Ainos, Inc.

Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets

2026-08-03 16:30:00

HOUSTON, TX / ACCESS Newswire / August 3, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced results for the second quarter ended June 30, 2026, and provided a business update on continued execution progress for AI Nose across semiconductor manufacturing, industrial infrastructure, robotics, and healthcare-related environments. Eddy Tsai, Chairman, President and Chief Executive Officer, commented: "We believe AI is increasingly expanding beyond understanding text, images, and speech toward interpreting real-world environmental information.

Ainos Expands Smell AI With Growing Real-World Scent Dataset for Physical AI

2026-07-21 09:00:00

AI Nose deployments have generated approximately 613 million industrial scent data points since December 2025, advancing Ainos' vision of a smell intelligence network HOUSTON, TX / ACCESS Newswire / July 21, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in Smell AI, today announced that its AI Nose deployments have generated approximately 613 million industrial scent data points since December 2025, primarily from semiconductor manufacturing environments. The milestone reflects the continued expansion of Ainos' Smell AI platform.

VASRO Research Highlights Ainos' Expansion of Smell AI Into Patient-Level Breath Intelligence

2026-06-22 09:00:00

HOUSTON, TX / ACCESS Newswire / June 22, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a new update report published by VASRO GmbH ("VASRO") reviewing Ainos' planned expansion of its AI Nose platform into patient-level breath intelligence. The VASRO update reviews Ainos' recently announced one-year research program with National Taiwan University, scheduled to begin on July 1, 2026, to evaluate whether AI-analyzed breath patterns may help distinguish acute exacerbations of chronic obstructive pulmonary disease ("COPD") from acute decompensated heart failure among patients presenting with shortness of breath.

Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program

2026-06-17 08:00:00

Program expands Ainos' Smell AI platform from environmental intelligence into digital breath intelligence for emergency medicine research HOUSTON, TX / ACCESS Newswire / June 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today announced a new research program with National Taiwan University ("NTU") to explore the use of Smell AI in emergency medicine. The program, titled "Rapid Diagnosis of Dyspneic Patients in the Emergency Department via AI-powered Electronic Nose Technology," will explore the use of Ainos' Smell AI platform to analyze volatile organic compounds ("VOCs") in exhaled breath.

Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

2026-06-08 08:00:00

Building the Olfactory Layer of Physical AI Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications HOUSTON, TX / ACCESS Newswire / June 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today released its 2026 Mid-Year Letter to Shareholders from Chairman, President and Chief Executive Officer Eddy Tsai. 2026 First Half Highlights Commercial Momentum Reported 499% year-over-year revenue growth during fiscal year 2025.

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

2026-06-05 08:00:00

HOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a recent report published by VASRO GmbH ("VASRO"), discussing the expansion of the Company's AI Nose platform into emergency department operations and the continued growth of its Smell ID data across diverse real-world environments. In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live emergency department environment to evaluate environmental scent analysis for emergency department overcrowding early warning and respiratory infection risk analysis.

Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study

2026-06-03 08:00:00

HOUSTON, TX / ACCESS Newswire / June 3, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced that Zacks Small-Cap Research ("Zacks SCR") has published a new article discussing Ainos' recently announced healthcare infrastructure study at National Taiwan University Hospital ("NTUH"). The article reviews Ainos' initiative to deploy AI Nose in a live emergency department environment and explores the potential role of Smell AI in environmental monitoring, healthcare infrastructure, and artificial intelligence applications.

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

2026-06-01 08:00:00

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure HOUSTON, TX / ACCESS Newswire / June 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced the launch of a research program at National Taiwan University Hospital ("NTUH"), one of Asia's leading academic medical centers, to deploy AI Nose inside a live emergency department environment for intelligent environmental monitoring, ER overcrowding early warning, and respiratory infection risk analysis. The program aims to expand Smell AI, powered by AI Nose, inside a real-world emergency department environment and expands market opportunities beyond semiconductor and industrial environments into frontline healthcare infrastructure.